Abstract: A gastric bypass device includes an occlusion device that is adapted to be deployed relative to a patient's pyloric sphincter, an anastomosis anchor that is adapted to be deployed relative to an anastomosis between the patient's stomach and their small intestine, and a tether that extends through the patient's small intestine between the occlusion device and the anastomosis anchor. A dynamic leash may be secured relative to the occlusion device and may work in conjunction with the tether to help hold the occlusion device in place. The gastric bypass device may be deployed using a variety of methods including a push-pull wire method, a rail method, a garage method, a two-piece method and a comprehensive method.

Abstract: A gastric bypass device includes an occlusion device that is adapted to be deployed relative to a patient's pyloric sphincter and a liner that extends distally from the occlusion device. A tether extends from the occlusion device. A dynamic leash may be secured relative to the occlusion device and may work in conjunction with the tether to help hold the occlusion device in place.

Abstract: This specification discloses a brain electrode device. The brain electrode device includes a set of contact points and a set of sub-circuits. The sub-circuits include sensor ports configured to connect to the contact to the respective ones of the contact points. The device can further include an intelligent multiplexer that aggregates signals from the set of sub-circuits and generates an aggregate signal. The aggregate signal is transmitted to a signal acquisition device.

Abstract: This document describes methods and devices for treating ventricular fibrillation. For example, this document describes methods of performing electroporation of a ventricle and electroporation catheters. The methods can include inserting a distal end portion of a catheter into a ventricle of a heart of a patient, inflating a balloon coupled to the distal end portion of the catheter, occluding a valve of the heart associated with the ventricle with the balloon, injecting a fluid into the ventricle via an aperture defined by the distal end portion of the catheter, and generating an electrical current via an electrode on the distal end portion of the catheter.

Abstract: Complexes containing a labeled polypeptide and an antibody, and the use of such complexes as research, diagnostic, and clinical tools, are described herein.

Abstract: Methods are provided herein for selectively killing senescent cells and for treating senescence-associated diseases and disorders by administering a senolytic agent. Senescence-associated diseases and disorders treatable by the methods using the senolytic agents described herein include cardiovascular diseases and disorders associated with or caused by arteriosclerosis, such as atherosclerosis; idiopathic pulmonary fibrosis; chronic obstructive pulmonary disease; osteoarthritis; senescence-associated ophthalmic diseases and disorders; and senescence-associated dermatological diseases and disorders.

Abstract: This document provides methods and materials related to selected engineered analogs of atrial natriuretic peptides. For example, this document provides compositions that contain one or more selected engineered analogs of atrial natriuretic peptides provided herein and that have the ability to treat, prevent, or alleviate the symptoms of cardiovascular, cardiorenal, and metabolic disease.

Abstract: The present invention relates to methods and compositions for determination of and uses of specific methylation patterns indicative of adenoma and carcinoma. In particular, the invention relates to analysis of defined CpG loci that are coordinately methylated in DNAs from cancer and adenoma samples, methods for identifying coordinately methylated loci, and methods of using analysis of coordinately methylated loci in one or more marker regions in the design of assays for adenoma and cancer.

Abstract: This document relates to methods and materials for identifying and/or treating mammals having cancer. For example, small extracellular vesicles (EVs), such as exosomes, obtained from a mammal suspected of having a cancer can be used to identify the mammal as having cancer and, optionally, the mammal can be treated.

Abstract: Some embodiments provide a soft tissue device, such as a transverse carpal ligament cutting device having one or more balloons that are deflated when the device is in an inactive position and are inflated when the device is in an active position. Other embodiments provide a soft tissue cutting method, such as a method of cutting a transverse carpal ligament that uses a soft tissue cutting device.

Abstract: This document provides materials and methods for identifying and quantifying AIM polypeptides in a sample using mass spectrometry techniques. For example, methods of using mass spectrometry to identify and quantify AIM polypeptides in a serum sample are provided. In some cases, quantification of AIM polypeptides can be used to diagnose and/or treat patients having a disease or disorder characterized by altered (e.g., increased or decreased) AIM polypeptide levels.

Abstract: The present disclosure generally relates to systems and methods of use for draining cerebrospinal fluid (CSF) from a brain or a spinal canal in a subject, for example, to treat hydrocephalus or other conditions. In some embodiments, the disclosure relates to a device comprising a flow controller positioned within a conduit that allows CSF to flow through the conduit from a first end to a second end. This may allow the CSF to drain, for example, from an intradural space (such as a thecal sac) into, for example, a paraspinal space, paraspinal vein or other venous space, or peritoneal cavity. A variety of methods may be used to hold or anchor the device in place, for example, an expansion apparatus. In some embodiments, the device can be implanted percutaneously at a location along or within a subject's spinal column, thus reducing the need for surgery, general anesthesia, and hospitalizations.

Abstract: The invention features methods of diagnosis by assessing B7-H1 expression in a tissue from a subject that has, or is suspected of having, cancer, methods of treatment with agents that interfere with B7-H1-receptor interaction, methods of selecting candidate subjects likely to benefit from cancer immunotherapy, and methods of inhibiting expression of B7-H1.

Abstract: In accordance with some embodiments, systems, methods, and media for automatically localizing and diagnosing thyroid nodules are provided. In some embodiments, a system for automatically diagnosing thyroid nodules comprises: an ultrasound machine; and a processor programmed to: receive a B-mode ultrasound of a thyroid from the ultrasound machine; provide the B-mode ultrasound to a classification model trained to automatically segment B-mode ultrasound; receive an output indicating which portions of the B-mode ultrasound correspond to a nodule; provide at least a portion of the B-mode ultrasound corresponding to the nodule to a second classification model trained to automatically classify thyroid nodules based B-mode, color Doppler, and shear wave elastography ultrasound; and receive, from the second trained classification model, an output indicative of the likelihood that the nodule is malignant.

Abstract: The invention provides a tissue cutting device comprising a handle, a first blade, and a second blade. The second blade is coupled to the handle. The second blade is rotatable relative to the first blade such that the second blade is configured to rotate between a first position and a second position. The second blade is in a same plane as the first blade when the second blade is in the first position. The second blade is rotated into a different plane from the first blade when the second blade is rotated from the first position toward the second position.

Abstract: The present invention relates to methods of treating subjects suffering from a pulmonary NTM infection refractory to treatment, for example to antibiotic treatment.

Abstract: This document provides methods and materials involved in killing HIV infected cells (e.g., CD4 T cells). For example, methods and materials for using one or more Bcl-2 inhibitors (e.g., ABT-199) alone or in combination with one or more agents capable of reactivating HIV (e.g., latency reversing agent) to kill HIV infected cells (e.g., CD4 T cells) are provided.

Abstract: Methods and materials for treating a mammal having a congenital disease (e.g., a congenital heart disease such as congenital long QT syndrome) are provided herein. For example, this document provides methods and materials for generating and using nucleic acids to treat a mammal having a congenital disease, where the nucleic acids can suppress expression of mutant disease-related alleles in the mammal while providing a replacement cDNA that does not contain the disease-related mutation(s).

Abstract: This document relates to methods and materials for virotherapy. For example, this document provides methods and materials for treating cancer using a recombinant mumps virus as an oncolytic agent.

Abstract: Systems, methods, devices, and techniques for estimating a heart disease prediction of a mammal. An electrocardiogram (ECG) procedure is performed on a mammal, and a computer system obtains ECG data that describes results of the ECG over a period of time. The system provides a predictive input that is based on the ECG data to a predictive model, such as a neural network or other machine-learning model. In response, the predictive model processes the input to generate an estimated heart disease predictive characteristic of the mammal. The system outputs the estimated heart disease prediction of the mammal for presentation to a user.